Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study / Sheppard, M; Bronstein, Md; Freda, P; Serri, O; De Marinis, L; Naves, L; Rozhinskaya, L; Hermosillo Reséndiz, K; Ruffin, M; Chen, Y; Colao, Annamaria. - In: PITUITARY. - ISSN 1386-341X. - (2015). [10.1007 / s11102-014-0628-z]

Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.

COLAO, ANNAMARIA
2015

2015
Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study / Sheppard, M; Bronstein, Md; Freda, P; Serri, O; De Marinis, L; Naves, L; Rozhinskaya, L; Hermosillo Reséndiz, K; Ruffin, M; Chen, Y; Colao, Annamaria. - In: PITUITARY. - ISSN 1386-341X. - (2015). [10.1007 / s11102-014-0628-z]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/599435
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact